Chinese authorities approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for its selevimab injection, according to a Wednesday filing with the Shanghai bourse.
The anti-rabies passive vaccine is indicated for children and adolescents aged 2 to 18 years after suspected exposure to the virus, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments